Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can one weekly workout beat fatty liver? new study tests the ideal exercise frequency

NCT ID NCT05741957

Symptom relief Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether exercising once a week or three times a week is better at reducing liver fat in adults who are centrally obese and have non-alcoholic fatty liver disease (NAFLD). Three hundred Chinese adults aged 18-69 will be assigned to either a once-weekly or thrice-weekly supervised treadmill program for 4 months. The goal is to find the most practical exercise frequency that still meets health recommendations and helps improve liver health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
supervised treadmill exercise program
What this could lead to
If it works, this could show that even once-a-week exercise can meaningfully reduce liver fat, offering a practical option for busy people with NAFLD.
What could go wrong
This is a behavioral study with no blinding, so results may be influenced by participants' expectations. The effect may be modest and not apply to all NAFLD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Cantonese, Mandarin, or English speaking Chinese; 2. Aged 18-69; 3. Male or female; 4. Centrally obese according to the Asian-specific cut-off (waist circumference ≥90 cm for males; ≥80 cm for females) and with BMI ≥23; 5. With NAFLD (defined as \>5% intrahepatic triglycerides assessed by 1H-MRS); 6. Willing to participate in exercise training to improve NAFLD. Exclusion Criteria: 1. Regular exercise training (\>3 sessions of \>60 min of moderate-intensity exercise training weekly) in the past 6 months; 2. Medical history of cardiovascular disease, chronic pulmonary or kidney disease, heart failure, cancer, and/or liver disease except NAFLD; 3. Somatic conditions that limit exercise participation (e.g., limb loss); 4. Impaired mobility due to chronic disease (e.g., chronic arthritis/osteoarthritis, neurological, musculoskeletal, and autoimmune diseases); 5. Daily smoking habit; 6. Excess alcohol consumption (daily ≥20 g of alcohol for men and ≥10 g for women) in the past 1 year; 7. Consumption of certain drugs (e.g., tamoxifen and estrogen) known to be secondary causes of steatosis; 8. Surgery, therapy, or medication for obesity or weight loss in the past 6 months (e.g., gastric bypass, gastric band, sleeve gastrectomy, gastric reduction duodenal switch, or dietitian-prescribed dietary program); 9. Physical changes that considerably affect body composition and weight (e.g., anorexia nervosa, bulimia nervosa, prolonged gastrointestinal and digestive disorders) during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Obesity, Abdominal Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease Obesity

Contacts and locations

Locations

  • LKS Faculty of Medicine

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.